BIOATLA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BIOATLA, INC. (BCAB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $13.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
- BIOATLA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $13.30M, a 21.76% decline from fiscal 2024.
- BIOATLA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $17.00M, a 41.18% decline from fiscal 2023.
- BIOATLA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $28.90M, a 23.50% increase from fiscal 2022.
- BIOATLA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $23.40M, a 13.59% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $13.30M 10-K · filed 2026-03-31 |
| 2024-12-31 | $17.00M 10-K · filed 2025-03-28 |
| 2023-12-31 | $28.90M 10-K · filed 2024-03-26 |
| 2022-12-31 | $23.40M 10-K · filed 2023-03-23 |
| 2021-12-31 | $20.60M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |